Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Published Time:
2021-03-08 18:01
Source:
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
Founded in 2010, Jiangsu Vcare specializes in end-to-end R&D, services, and innovation across the chemical drug industry chain. Headquartered in Nanjing Biotech and Pharmaceutical Valley, the company employs 280 staff, with over 50% of its R&D team holding master’s or doctoral degrees. It operates a 21,000 sqm high-end drug R&D center equipped with fully functional synthesis, analysis, formulation, cell, and enzyme activity testing laboratories. Its experienced teams in medicinal chemistry, CMC, and clinical development operate under internationally advanced management models, providing comprehensive R&D capabilities spanning "Chemistry + Pharmacy + Medicine".
Focusing on unmet clinical needs in cardiovascular, oncology, and endocrine diseases, Jiangsu Vcare has developed multiple competitive innovative products through independent R&D and collaborative innovation. Its flagship drug Vicagrel—which has completed Phase II trials—was recognized as "one of the most commercially promising projects in its field." The second-generation NTRK inhibitor has entered Phase I, while a highly selective JAK1 inhibitor is nearing IND submission. The pipeline includes multiple first-in-class (FIC) and best-in-class (BIC) preclinical candidates.
In recent years, Jiangsu Vcare has steadily advanced its innovative drug programs while achieving rapid growth in contract services. With investor support, the company aims to accelerate clinical research and deliver more high-quality therapeutics to global patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "We sincerely appreciate our investors’ recognition of Jiangsu Vcare and their trust in our team. We are in an exhilarating era of innovation, where developing novel drugs to address clinical needs remains our unwavering mission. Simultaneously, in this service-driven economy, we are committed to providing one-stop, full-process drug R&D services that create value for clients. Moving forward, we will continue to prioritize independent innovation and open collaboration to unlock limitless potential."
Next Page
Next Page
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn